跳至主要内容
临床试验/NCT01715493
NCT01715493已完成4 期

Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom: a Randomised Placebo-controlled Study

Eisai Co., Ltd.0 个研究点目标入组 48 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
48
主要终点
Change of several inflammatory or biochemical marker concentration in inducted sputum

研究概览

简要总结

The aim of this study was to assess the effectiveness for small airway inflammation of 4 weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 84 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Lysozyme 90 mg

Experimental

干预措施: lysozyme 90 mg (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Change of several inflammatory or biochemical marker concentration in inducted sputum

时间窗: 8 weeks (2 periods each lasting 4 weeks)

Peripheral airway resistance and reactance measured by Impulse oscillometry system, and NO concentration.

时间窗: 8 weeks (2 periods each lasting 4 weeks)

次要结局

  • Monthly reduction in forced expiratory volume in 1 Second (FEV1)(8 weeks (2 periods each lasting 4 weeks))
  • Quality of life assessed by CAT (COPD Assessment Test) and ACT (Asthma Control Test)(8 weeks (2 periods each lasting 4 weeks))

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Pharmacological Effect of Lysozyme for Chronic... | 临床试验